| Mon, 14 Oct 2019 13:20:21: | Marrying CRISPR with immuno-oncology to defeat remote tumors
|
| Mon, 14 Oct 2019 12:48:55: | BridgeBio scraps plan to buy Eidos after bids rebuffed
|
| Mon, 14 Oct 2019 12:14:19: | ReNeuron shares clinical data on stem cell vision loss therapy
|
| Mon, 14 Oct 2019 10:19:31: | CAR-T cells as 'bait' show promise in autoimmune diseases
|
| Mon, 14 Oct 2019 09:12:52: | Covance clinical development lead takes the reins at Pharm-Olam
|
| Fri, 11 Oct 2019 15:45:38: | Koalas shed light on DNA's ability to resist cancer-causing viruses
|
| Fri, 11 Oct 2019 13:20:32: | Pfizer posts detailed phase 3 data on its Dupixent rival
|
| Fri, 11 Oct 2019 11:38:44: | Aridis nabs pharma veteran as ex-CMO leaves for 'personal reasons' after drug flop
|
| Fri, 11 Oct 2019 10:51:55: | Gilead, Galapagos share 52-week update on filgotinib
|
| Fri, 11 Oct 2019 10:21:56: | Five Prime's new CEO wields ax, laying off 70 staffers
|
| Thu, 10 Oct 2019 18:50:38: | Chutes & Ladders—Gilead Sciences nabs ex-Genentech exec Parsey as next CMO
|
| Thu, 10 Oct 2019 13:28:48: | J&J offloads midphase pain program to Neumentum
|
| Thu, 10 Oct 2019 12:41:35: | Alexion bags option on Stealth's phase 3 rare disease drug
|
| Thu, 10 Oct 2019 09:08:58: | UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris
|
| Thu, 10 Oct 2019 07:11:53: | Parexel pens Datavant tech deal for trial workflows
|
| Wed, 09 Oct 2019 15:25:53: | How Viagra could boost a widely used blood cancer treatment
|
| Wed, 09 Oct 2019 12:24:36: | Novo taps bluebird bio for gene-editing tech
|
| Wed, 09 Oct 2019 12:15:51: | Bayer forms drug discovery pact with Japan's Riken Innovation
|
| Wed, 09 Oct 2019 08:37:22: | Greenwood to step down as CEO of BIO after 2020 election
|
| Tue, 08 Oct 2019 12:51:54: | Merck taps 4D pharma for bacterial vaccine R&D project
|
| Tue, 08 Oct 2019 12:11:34: | Chasing AbbVie, Gilead files for approval of filgotinib in Japan
|
| Tue, 08 Oct 2019 07:42:43: | Chinese infectious disease biotech Ascletis nabs Novartis exec as CSO
|
| Mon, 07 Oct 2019 13:33:27: | Early readout from small NGM study shows NASH drug hits liver fat, but shares fall
|
| Mon, 07 Oct 2019 13:16:41: | Amid C-suite shake-up, Gilead nabs Genentech exec as new CMO
|
| Mon, 07 Oct 2019 12:49:25: | Oxford spinout MiroBio bags £27M for autoimmune R&D
|
